Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages

Priyanka Saminathan, Bhavesh D. Kevadiya, Daniel F. Marker, Howard Eliot Gendelman, Santhi Gorantla, Harris A. Gelbard

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Mixed lineage kinases (MLKs) are a group of serine-threonine kinases that evolved in part to respond to endogenous and exogenous insults that result in oxidative stress and pro-inflammatory responses from innate immune cells. Human immunodeficiency virus type 1 (HIV-1) thrives in these conditions and is associated with the development of associated neurocognitive disorders (HAND). As part of a drug discovery program to identify new therapeutic strategies for HAND, we created a library of broad spectrum MLK inhibitors with drug-like properties. Serendipitously, the lead compound, URMC-099 has proved useful not only in reversing damage to synaptic architecture in models of HAND, but also serves to restore autophagy as a protective response when given in concert with nanoformulated antiretroviral therapy (nanoART) in persistently infected macrophages. These findings are reviewed in the context of MLK3 biology and cellular signaling pathways relevant to new HIV-1 therapies. [Figure not available: see fulltext.].

Original languageEnglish (US)
Pages (from-to)44-51
Number of pages8
JournalJournal of Neuroimmune Pharmacology
Volume14
Issue number1
DOIs
StatePublished - Mar 15 2019

Fingerprint

HIV-1
Macrophages
Phosphotransferases
Protein-Serine-Threonine Kinases
Autophagy
Drug Discovery
Innate Immunity
Cell Biology
Oxidative Stress
Therapeutics
Pharmaceutical Preparations
Inhibition (Psychology)
mitogen-activated protein kinase kinase kinase 11
URMC-099
Lead
Neurocognitive Disorders

Keywords

  • Autophagy
  • Central nervous system
  • Human immunodeficiency virus type 1
  • Macrophage
  • Mixed lineage kinase

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. / Saminathan, Priyanka; Kevadiya, Bhavesh D.; Marker, Daniel F.; Gendelman, Howard Eliot; Gorantla, Santhi; Gelbard, Harris A.

In: Journal of Neuroimmune Pharmacology, Vol. 14, No. 1, 15.03.2019, p. 44-51.

Research output: Contribution to journalReview article

Saminathan, Priyanka ; Kevadiya, Bhavesh D. ; Marker, Daniel F. ; Gendelman, Howard Eliot ; Gorantla, Santhi ; Gelbard, Harris A. / Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages. In: Journal of Neuroimmune Pharmacology. 2019 ; Vol. 14, No. 1. pp. 44-51.
@article{137adabb6c8345889d9620d90dea23b7,
title = "Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages",
abstract = "Mixed lineage kinases (MLKs) are a group of serine-threonine kinases that evolved in part to respond to endogenous and exogenous insults that result in oxidative stress and pro-inflammatory responses from innate immune cells. Human immunodeficiency virus type 1 (HIV-1) thrives in these conditions and is associated with the development of associated neurocognitive disorders (HAND). As part of a drug discovery program to identify new therapeutic strategies for HAND, we created a library of broad spectrum MLK inhibitors with drug-like properties. Serendipitously, the lead compound, URMC-099 has proved useful not only in reversing damage to synaptic architecture in models of HAND, but also serves to restore autophagy as a protective response when given in concert with nanoformulated antiretroviral therapy (nanoART) in persistently infected macrophages. These findings are reviewed in the context of MLK3 biology and cellular signaling pathways relevant to new HIV-1 therapies. [Figure not available: see fulltext.].",
keywords = "Autophagy, Central nervous system, Human immunodeficiency virus type 1, Macrophage, Mixed lineage kinase",
author = "Priyanka Saminathan and Kevadiya, {Bhavesh D.} and Marker, {Daniel F.} and Gendelman, {Howard Eliot} and Santhi Gorantla and Gelbard, {Harris A.}",
year = "2019",
month = "3",
day = "15",
doi = "10.1007/s11481-018-09829-8",
language = "English (US)",
volume = "14",
pages = "44--51",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages

AU - Saminathan, Priyanka

AU - Kevadiya, Bhavesh D.

AU - Marker, Daniel F.

AU - Gendelman, Howard Eliot

AU - Gorantla, Santhi

AU - Gelbard, Harris A.

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Mixed lineage kinases (MLKs) are a group of serine-threonine kinases that evolved in part to respond to endogenous and exogenous insults that result in oxidative stress and pro-inflammatory responses from innate immune cells. Human immunodeficiency virus type 1 (HIV-1) thrives in these conditions and is associated with the development of associated neurocognitive disorders (HAND). As part of a drug discovery program to identify new therapeutic strategies for HAND, we created a library of broad spectrum MLK inhibitors with drug-like properties. Serendipitously, the lead compound, URMC-099 has proved useful not only in reversing damage to synaptic architecture in models of HAND, but also serves to restore autophagy as a protective response when given in concert with nanoformulated antiretroviral therapy (nanoART) in persistently infected macrophages. These findings are reviewed in the context of MLK3 biology and cellular signaling pathways relevant to new HIV-1 therapies. [Figure not available: see fulltext.].

AB - Mixed lineage kinases (MLKs) are a group of serine-threonine kinases that evolved in part to respond to endogenous and exogenous insults that result in oxidative stress and pro-inflammatory responses from innate immune cells. Human immunodeficiency virus type 1 (HIV-1) thrives in these conditions and is associated with the development of associated neurocognitive disorders (HAND). As part of a drug discovery program to identify new therapeutic strategies for HAND, we created a library of broad spectrum MLK inhibitors with drug-like properties. Serendipitously, the lead compound, URMC-099 has proved useful not only in reversing damage to synaptic architecture in models of HAND, but also serves to restore autophagy as a protective response when given in concert with nanoformulated antiretroviral therapy (nanoART) in persistently infected macrophages. These findings are reviewed in the context of MLK3 biology and cellular signaling pathways relevant to new HIV-1 therapies. [Figure not available: see fulltext.].

KW - Autophagy

KW - Central nervous system

KW - Human immunodeficiency virus type 1

KW - Macrophage

KW - Mixed lineage kinase

UR - http://www.scopus.com/inward/record.url?scp=85059684353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059684353&partnerID=8YFLogxK

U2 - 10.1007/s11481-018-09829-8

DO - 10.1007/s11481-018-09829-8

M3 - Review article

VL - 14

SP - 44

EP - 51

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 1

ER -